PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N ®, will be featured as part of a new experimental program designed to potentially limit the spread and lethality of the pandemic influenza virus designated H7N9. Professor Richt, Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), will present his program to potentially reduce the spread of influenza from animals to man. Professor Richt, who is a scientific adviser to Hemispherx Biopharma, will discuss new experiments on the possible inhibition of Tamiflu-resistant H7N9 virus by Alferon N ® and the potential use of Alferon ® LDO (a low dose oral formulation of Alferon N ®) in animals that are considered "mixing vessels" in that they support potential influenza reassortment and virulence. The conference will take place at the Holiday Inn, Orlando International Airport, on August 21-23.
Director Of The U.S. Department Of Homeland Security Center Of Excellence For Emerging And Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., To Present Programs To Reduce - Influenza Spread
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts